Corium’s Azstarys (serdexmethylphenidate and dexmethylphenidate) Receives the US FDA’s Approval for ADHD in Patients Aged 6 Years and Older

 Corium’s Azstarys (serdexmethylphenidate and dexmethylphenidate) Receives the US FDA’s Approval for ADHD in Patients Aged 6 Years and Older

Corium’s Azstarys (serdexmethylphenidate and dexmethylphenidate) Receives the US FDA’s Approval for ADHD in Patients Aged 6 Years and Older

Shots:

  • The approval is based on a P-III study that involves assessing Azstarys (qd) vs PBO in 150 children aged 6-12yrs. with ADHD
  • The study showed improvement in 1EPs i.e. ADHD symptoms, reduction in SKAMP-C score (-5.4points)
  • Azstarys is the first and only product containing a d-MPH oral prodrug for the treatment of ADHD and will be available as 3 dosage strength- 26.1/5.2 mg, 39.2/7.8 mg, and 52.3/10.4 mg with the anticipated launch in summer 2021

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post